Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation
A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Clinical Research Unit
Salt Lake City, Utah, United States
Start Date
May 1, 2011
Primary Completion Date
May 1, 2012
Completion Date
June 1, 2012
Last Updated
January 25, 2021
69
ACTUAL participants
TD-1211
DRUG
Placebo
DRUG
Lead Sponsor
Theravance Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions